Top

Outcomes of Plasma Cell Myeloma Patients with t(4;14) who underwent Autologous Hematopoietic Cell Transplantation

Chronic Malignancies Working Party (CMWP)
Study type:
Retrospective Studies
Study number:
42206713
Type of treatment:
Autologous
Diseases:
Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)
Short title:
Auto-HCT for t(4;14) plasma cell myeloma
Primary objective:
To assess survival outcomes (PFS, OS) after auto-HCT in patients with PCM harbouring t(4;14)
Key inclusion criteria:
Adults
PCM with t(4;14)
First auto-HCT(s) (both single and tandem)
Period Analysed: 2016-2022
Country:
All EBMT member countries
Principal investigator:
Joanna Drozd-Sokolowska/Patrick Hayden
EBMT Study coordinator:
Linda Koster
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No

Privacy notices

Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)

Data Protection Impact Assessments

Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results